Please check your internet connection and try again.
# Ecospirin (Aspirin, Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and antiplatelet properties. The enteric coating delays release of aspirin until it reaches the small intestine, reducing gastric irritation.
## Primary Indications
* **Cardiovascular risk reduction:** Prevention of myocardial infarction and stroke in patients with known cardiovascular disease or risk factors.
* **Analgesia and antipyresis:** Relief of mild to moderate pain and fever. (Note: Enteric-coated aspirin is generally not preferred for acute pain/fever due to delayed onset of action).
* **Rheumatic conditions:** Management of inflammatory conditions like rheumatoid arthritis or osteoarthritis (higher doses typically used, often not enteric-coated).
## Adult Dosing
* **Cardiovascular prevention:** Typically 75 mg to 150 mg once daily. Doses may vary based on individual risk assessment and local protocols.
* **Analgesia/Antipyresis:** 325 mg to 650 mg every 4 to 6 hours as needed. Maximum daily dose generally 4000 mg.
* **Rheumatic conditions:** Doses vary widely, often starting at 325 mg to 650 mg every 4 to 6 hours, with potential titration up to 4000 mg to 6000 mg per day in divided doses.
## Pediatric Dosing
Aspirin is generally **contraindicated** in children and teenagers younger than 19 years with viral infections (e.g., influenza, varicella) due to the risk of Reye's syndrome. Specific pediatric dosing for approved indications outside of this contraindication is not well-established for enteric-coated formulations and should be guided by specialist consultation and current pediatric guidelines.
## Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment, but caution is advised, and lower doses may be considered, especially in severe impairment. Aspirin is highly protein-bound and may be displaced by other drugs.
## Contraindications
* Known hypersensitivity to aspirin, salicylates, NSAIDs, or any component of the formulation.
* Active gastrointestinal bleeding or ulceration.
* History of GI bleeding or perforation related to prior NSAID use.
* Children and teenagers younger than 19 years with viral infections.
* Severe hepatic impairment.
* Severe renal impairment (CrCl < 30 mL/min).
* Uncontrolled hypertension.
* Hemophilia, thrombasthenia, or other bleeding disorders.
* Third trimester of pregnancy.
## Adverse Effects
* **Common:** Dyspepsia, heartburn, nausea, abdominal pain, increased bleeding risk (bruising, epistaxis, prolonged bleeding time).
* **Serious:** Gastrointestinal ulceration and bleeding, tinnitus, hearing loss (especially at higher doses), bronchospasm (in aspirin-sensitive asthma), hypersensitivity reactions, Reye's syndrome (in children/adolescents with viral illness), renal toxicity, hepatic toxicity.
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding. Concurrent use requires careful monitoring.
* **Other NSAIDs and COX-2 inhibitors:** Increased risk of GI toxicity and bleeding; generally avoid concurrent use.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs):** Increased risk of bleeding.
* **Methotrexate:** Increased methotrexate toxicity due to decreased renal clearance.
* **Uricosuric agents (e.g., probenecid):** Aspirin may decrease the efficacy of these agents.
* **Antihypertensives:** Aspirin may reduce the efficacy of some antihypertensive agents (e.g., ACE inhibitors, beta-blockers).
* **Alcohol:** Increased risk of GI irritation and bleeding.
## Monitoring
* **Signs and symptoms of GI bleeding:** Melena, hematemesis, abdominal pain.
* **Signs and symptoms of hypersensitivity:** Rash, urticaria, bronchospasm.
* **Tinnitus and hearing changes:** May indicate salicylate toxicity.
* **Bleeding:** Monitor for bruising, prolonged bleeding from cuts, epistaxis.
* **Renal function and electrolytes:** Especially in patients with pre-existing renal disease or those on long-term therapy.
## Clinical Pearls
* Enteric coating is intended to reduce gastric irritation but does not eliminate the risk of GI bleeding. Swallow tablets whole; do not crush, chew, or break.
* For acute pain or fever, immediate-release aspirin formulations are preferred due to faster onset of action.
* The antiplatelet effect of aspirin is irreversible and lasts for the life of the platelet (7-10 days).
* Discontinue aspirin at least 5-7 days prior to elective surgery, unless otherwise directed by the prescribing physician.
* Consider alternatives in patients with a history of peptic ulcer disease or significant GI risk factors.
***
*This information is intended for healthcare professionals. Always consult the official prescribing information and current clinical guidelines for the most up-to-date and complete information before making any treatment decisions.*
